Increased risk of bladder cancer with pioglitazone therapy in patients with diabetes: A meta-analysis

Diabetes Research and Clinical Practice

Volumn 98, Issue 1, 2012, Pages 159-163

  Zhu, Zhaowei ^a   Shen, Zhoujun ^a   Lu, Yingli ^a   Zhong, Shan ^a   Xu, Chen ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Bladder cancer; Diabetes; Pioglitazone

Indexed keywords

PIOGLITAZONE;

ARTICLE; BLADDER CANCER; CANCER INCIDENCE; CANCER RISK; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; GENETIC HETEROGENEITY; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; RISK ASSESSMENT; SYSTEMATIC REVIEW; TREATMENT DURATION;

DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; RISK FACTORS; THIAZOLIDINEDIONES; URINARY BLADDER NEOPLASMS;

EID: 84867395333     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2012.05.006     Document Type: Article

References (18)

1. Jemal A., Siegel R., Xu J., Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010, 60:277-300.
2. Larsson S.C., Orsini N., Brismar K., Wolk A. Diabetes mellitus and risk of bladder cancer: a meta-analysis. Diabetologia 2006, 49:2819-2823.
3. Li C., Balluz L.S., Ford E.S., Okoro C.A., Tsai J., Zhao G. Association between diagnosed diabetes and self-reported cancer among U.S. adults: findings from the 2009 behavioral risk factor surveillance system. Diabetes Care 2011, 34:1365-1368.
4. MacKenzie T., Zens M.S., Ferrara A., Schned A., Karagas M.R. Diabetes and risk of bladder cancer: evidence from a case-control study in New England. Cancer 2011, 117:1552-1556.
5. Tseng C.H. Diabetes and risk of bladder cancer: a study using the National Health Insurance database in Taiwan. Diabetologia 2011, 54:2009-2015.
6. Nathan D.M., Buse J.B., Davidson M.B., Ferrannini E., Holman R.R., Sherwin R., et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009, 32:193-203.
7. Cohen S.M. Effects of PPAR gamma and combined agonists on the urinary tract of rats and other species. Toxicol Sci 2005, 87:322-327.
8. Lewis J.D., Ferrara A., Peng T., Hedderson M., Bilker W.B., Quesenberry C.P., et al. Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study. Diabetes Care 2011, 34:916-922.
9. Dormandy J.A., Charbonnel B., Eckland D.J., Erdmann E., Massi-Benedetti M., Moules I.K., et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005, 366:1279-1289.
10. Dormandy J., Bhattacharya M., de Bruyn A.R.v.T. Safety and tolerability of pioglitazone in high-risk patients with type 2 diabetes: an overview of data from PROactive. Drug Saf 2009, 32:187-202.
11. Chang C.H., Lin J.W., Wu L.C., Lai M.S., Chuang L.M., Chan K.A. Association of thiazolidinediones with liver cancer and colorectal cancer in type 2 diabetes mellitus. Hepatology 2012, 55:1462-1472. 10.1002/hep.25509.
12. Piccinni C., Motola D., Marchesini G., Poluzzi E. Assessing the association of pioglitazone use and bladder cancer through drug adverse event reporting. Diabetes Care 2011, 34:1369-1371.
13. Tseng C.H. Pioglitazone and bladder cancer: a population-based study of Taiwanese. Diabetes Care 2012, 35:278-280.
14. Neumann A., Weill A., Ricordeau P., Fagot J.P., Alla F., Allemand H. Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study. Diabetologia 2012, 55:1953-1962.
15. Yoshimura R., Matsuyama M., Segawa Y., Hase T., Mitsuhashi M., Tsuchida K., et al. Expression of peroxisome proliferator-activated receptors (PPARs) in human urinary bladder carcinoma and growth inhibition by its agonists. Int J Cancer 2003, 104:597-602.
16. Tannehill-Gregg S.H., Sanderson T.P., Minnema D., Voelker R., Ulland B., Cohen S.M., et al. Rodent carcinogenicity profile of the antidiabetic dual PPAR alpha and gamma agonist muraglitazar. Toxicol Sci 2007, 98:258-270.
17. Lubet R.A., Fischer S.M., Steele V.E., Juliana M.M., Desmond R., Grubbs C.J. Rosiglitazone, a PPAR gamma agonist: potent promoter of hydroxybutyl(butyl)nitrosamine-induced urinary bladder cancers. Int J Cancer 2008, 123:2254-2259.
18. Oliveria S.A. Cancer incidence among patients treated with antidiabetic pharmacotherapy. Diabetes Metab Synd 2008, 2:47-57.